American Urological Association - Evidence-Based Clinical Management of Advanced and Castration-Resistant Prostate Cancer

advertisement

Home Education Educational Calendar 2018 Advanced and Castration-Resistant Prostate Cancer Course

Evidence-Based Clinical Management of Advanced and Castration-Resistant Prostate Cancer

Overview/Register

There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC). To this end, the AUA created this course as part of its educational initiative to focus on resident and fellow training in the area of advanced prostate cancer and CRPC.

Maximum of 9.25 AMA PRA Category 1 Credits

The Changing Landscape of
Advanced Prostate Cancer Management

Online

Emerging Treatment of M0 CRPC:
Update on the AUA/SUO Guidelines

Online

Androgen Axis Agents and
Bone Target Therapies in
Advanced Prostate Cancer

Online

Sequencing of
Chemotherapy and Immunotherapy in
Advanced Prostate Cancer

Online
        Live Course (Fall)         
Phoenix, AZ
November 27, 2018

Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).Society of Urologic Oncology

Course Co-Directors

Michael S. Cookson, MD, MMHC
David F. Jarrard, MD

Target Audience

This activity is designed for urology residents, fellows, advanced practice providers, urologists and other health care providers who care for patients with prostate cancer.

Course Description

There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC).  The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area. Additionally, the findings indicate that the AUA should continue to develop courses and educational materials specifically targeted at residents that covers the medical management of advanced prostate cancer.

The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer (CRPC). Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.

The 2018 series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts.

All activities are complimentary.

As the capstone to this initiative, a live, interactive forum will be held for participants to engage with subject matter expects and mentors.  For convenience, participants can choose from one of two dates and locations.


Learning Objectives                                                                       

At the conclusion of this activity, participants will be able to:  

Practice Gap #1 (Disease State)

  1. Describe the natural course of advanced prostate cancer from non-metastatic to metastatic hormone-sensitive disease, with progression to the development of castration-resistant disease.
  2. Describe the treatment options and outcomes for newly diagnosed metastatic hormone-sensitive prostate cancer.
  3. Explain the implications of CRPC on the management of both M0 and M1.
  4. Discuss the molecular mechanisms and characterization of CRPC.

Practice Gap #2 (Guidelines)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.

Practice Gap #3 (Androgen Axis)

  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.

Practice Gap #4 (Chemotherapy and Immunotherapy and Co-Morbidity)

  1. Identify approved chemotherapeutics and immunotherapy for mCRPC.
  2. Describe indications and contraindications for chemotherapy and immunotherapy in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.

Practice Gap #5 (Bone Health and Radionuclide Therapy)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.

Practice Gaps #6 (Pain Management and Palliative Care)

  1. Assess and manage pain in patients with CRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.

Live Forum - Scientific Program

Scientific Program Schedule 

9 a.m. - 10 a.m.

Registration/Arrivals

10 a.m. – 10:10 a.m.

Welcome
Michael S. Cookson, MD, MMHC & David Jarrard, MD

10:10 a.m. – 10:25 a.m.

Pre-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Session I

10:25 a.m. – 10:45 a.m.

Initial Management and Imaging of Advanced Prostate Cancer
Todd Matthew Morgan, MD

10:45 a.m. – 11:05 a.m.

Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Alicia Morgans, MD, MPH

11:05 a.m. – 11:25 a.m.

M0 CRPC: Emerging Treatment Options
Alicia Morgans, MD, MPH

11:25 a.m. – 11:45 a.m.

MDC and Review of CRPC Guidelines
Michael S. Cookson, MD, FACS

11:45 a.m. – 12:15 p.m.

Case-Based Roundtable Discussions - Session I

12:15 p.m. - 12:20 p.m.

Session I Post-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

12:20 p.m. - 1:35 p.m.

A Non-CME Lunch Symposium supported by Astellas Pharma US and Pfizer Oncology

Session II

1:35 p.m. – 1:55 p.m.

Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents
David F. Jarrard, MD, FACS

1:55 p.m. – 2:15 p.m.

Radionuclide Therapy and Bone Health
Kelly L. Stratton, MD

2:15 p.m. – 2:45 p.m.

Cased-based Roundtable Discussions - Session II
All Faculty

2:45 p.m. – 2:50 p.m.

Session II Post-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

2:50 p.m – 3:10 p.m.

Break

Session III

3:10 p.m. – 3:40 p.m.

Role of Chemotherapy and Performance Status and Pain Management
Robert Driecer, MD

3:40 p.m. – 4:00 p.m.

Treatment Sequencing, Immunotherapy and Future Approaches
Kelly Stratton, MD

4:00 p.m. – 4:40 p.m.

Case-based Roundtable Discussion - Session III
All Faculty

4:40 p.m. – 4:45 p.m.

Session III Post-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

4:45 p.m. – 5 p.m.

Closing Remarks
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Hotel & Transportation

Live Course & Hotel Information – November 27, 2018

Sheraton Grand Phoenix
340 North 3rd Street
Phoenix, AZ 85004

View More Information

Live Webinar Series

Live Webinar Series

Online
July-October







Interact with the subject matter experts during four, live interactive webinars. For convenience, webinars will be limited to just one hour. Time and dates coming soon! 

Can't make it to the live webinars?  Content will be recorded and made available on AUAUniversity so that you can view a webcast or listen via podcast at a time and date that works best for you.     

Webinar #1: The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know

  • Initial Management and Imaging of Advanced Prostate Cancer
  • Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer  

Webinar #2: Emerging Treatment of M0 CRPC: Update on the AUA/SUO Guidelines and Beyond

  • M0 CRPC: Emerging Treatment Options
  • MDC and Review of CRPC Guidelines

Webinar #3: Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New

  • Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents
  • Radionuclide Therapy and Bone Health

Webinar #4: Sequencing of Chemotherapy and Immunotherapy in Advanced Prostate Cancer: Present and Future

  • Role of Chemotherapy and Performance Status and Pain Management
  • Treatment Sequencing, Immunotherapy and Future Approaches      

Co-Directors                               

Michael S. Cookson, MD, MMHC
Professor and Chairman
University of Oklahoma - Department of Urology
Oklahoma City, OK      

David F. Jarrard, MD
Professor and Vice Chairman of Clinical Affairs
University of Wisconsin School of Medicine and Public Health
Madison, WI

Registration Fees

Registration Fees                                                            

All activities are complimentary.

Cancellation Policy

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before April 5, 2018. If AUA Education & Research cancels this course, notification will be sent by April 12, 2018.

Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.

Attendee Information & Policies

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images

Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions and audiotapes of such events and activities.  

Audio, Video, Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance/Dietary Needs

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

CME Information

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity and enduring material for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstration.
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Acknowledgements

This educational series is supported by independent educational grants from:

  • Astellas and Pfizer Inc.
  • Ferring Pharmaceuticals Inc.
  • Genomic Health
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Sanofi Genzyme
  • Tolmar Pharmaceuticals, Inc.

Patient Education Materials

To encourage and support the participant's care of their patients, this activity will provide resources to Urology Care Foundation existing resources on CRPC. These resources will include patient videos and brochures.

Advertisement

Advertisement

advertisement

advertisement

The New AUAnet

Tips

Website Tip!

While viewing Guideline Statements on a desktop computer, use the left navigation to jump to different parts of the page.